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Background/Aims: Serum sodium predicts prognosis in cirrhosis and may improve the prognostic accuracy
of the model for end-stage liver disease (MELD) score, but the available information is limited. The aim of the
present study was to assess the prognostic value of serum sodium in the prediction of survival at 3 and
12 months after listing in patients with cirrhosis awaiting liver transplantation, and to compare its predictive
value with that of the MELD score.
Patients and methods: 308 consecutive patients with cirrhosis listed for transplantation during a 5-year
period were included in the study. The end-point was survival at 3 and 12 months before transplantation.
Variables obtained at the time of listing were analysed for prognostic value using multivariable analysis.
Accuracy of prognostic variables was analysed by receiver operating characteristic (ROC) curves.
Results: The MELD score and serum sodium concentration were the only independent predictors of survival at
3 and 12 months after listing. Low serum sodium was associated with an increased risk of death in all
subpopulations of patients with cirrhosis categorised according to the major complication developed before
listing. The area under the ROC curves for serum sodium and MELD score was not significantly different both
at 3 months (0.83 vs 0.79, respectively) and at 12 months (0.70 vs 0.77, respectively). The addition of serum
sodium did not significantly improve the accuracy of the MELD score in the prediction of survival at 3 and
12 months.
Conclusion: In patients with cirrhosis awaiting liver transplantation, serum sodium and MELD were found to
be independent predictors of survival. Larger studies are needed to determine whether the addition of serum
sodium to MELD can improve its prognostic accuracy.
T
he model for end-stage liver disease (MELD) score is the
method most widely used for organ allocation in liver
transplantation.1–3 This model, which includes variables
related to both liver and renal function, was implemented in
the USA in 2002 and is currently being used in many countries
to classify patients with cirrhosis awaiting transplantation
according to the severity of their liver disease. Nevertheless,
several studies, as well as clinical observation, indicate that
some subsets of patients with cirrhosis may have high mortality
despite low MELD scores.4–7 Therefore, there is need for
improvement of the MELD score. In this regard, several recent
studies have shown that serum sodium concentration is a good
marker of prognosis in patients awaiting transplantation.8–10
According to the results of these studies, the use of serum
sodium in the assessment of severity of cirrhosis has been
recommended. However, there are several issues on the possible
use of serum sodium as a predictor of prognosis that require
more information, specifically: (1) whether the value of serum
sodium is equally effective in the assessment of short-term
prognosis (3 months) compared with mid-term prognosis
(12 months); (2) whether serum sodium is equally accurate
in predicting prognosis in different subpopulations of patients
with cirrhosis; and (3) whether serum sodium improves the
accuracy of the MELD score. The purpose of this study was to
investigate these issues.
PATIENTS AND METHODS
Study population
This is a single-centre retrospective cohort study of all adult
patients with cirrhosis listed for liver transplantation at the
Hospital Clı´nic of Barcelona during the period between January
2000 and March 2005. During this period, a total of 560 patients
were listed for transplantation. Two hundred and fifty-two
patients were excluded from this study for the following
reasons: hepatocellular carcinoma (n = 152), retransplantation
(n = 48) or diseases other than cirrhosis (acute liver failure,
n = 22; familial amyloidotic polyneuropathy, n = 18; or mis-
cellaneous disorders, n = 12). Patients in whom hepatocellular
carcinoma was diagnosed after listing (n = 2) and those who
were found to have incidental hepatocellular carcinoma at
transplantation (n = 12) were not excluded from the study. The
study cohort included 308 patients with cirrhosis.
Criteria for listing patients with cirrhosis for liver transplan-
tation throughout the study period were the existence of
decompensated liver disease together with moderate-to-severe
liver failure, as indicated by a Child–Pugh score >7, and
absence of absolute contraindications for transplantation.
Patients belonging to Child–Pugh class A were only considered
for transplantation if they had developed hepatic encephalo-
pathy or had a concomitant parenchymal renal disease
requiring combined liver–kidney transplantation.11 12 At the
time of listing, demographic, clinical and biochemical variables
were collected and included in a specific database for patients
awaiting transplantation.
Once included on the waiting list, patients were followed-up
by experienced hepatologists, and complications of cirrhosis
were treated according to standardised therapeutic protocols as
follows. Moderate ascites was treated with low-sodium diet and
diuretics (spironolactone alone or in combination with furose-
mide), and large ascites was treated with large-volume
paracentesis plus albumin, followed by low-sodium diet and
Abbreviations: INR, international normalisation ratio; MELD, model for
end-stage liver disease; ROC, receiver operating characteristic
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diuretics, as described in detail elsewhere.13 14 Ascites at the
time of listing was classified as controlled or uncontrolled
according to the score obtained in the Child–Pugh classifica-
tion, 2 or 3, respectively.15 16 Spontaneous bacterial peritonitis
was treated with ceftriaxone plus intravenous albumin,
followed by the administration of norfloxacin to prevent
recurrence.14 17 Dilutional hyponatraemia (serum sodium
,130 mEq/l) was managed with fluid restriction (1–1.5 l/
day), except for those patients with severe hyponatraemia
(serum sodium ,120 mEq/l), who were given hypertonic saline
before transplantation in an attempt to increase serum sodium
concentration. Hepatorenal syndrome with serum creatinine
above 2 mg/dl was managed with terlipressin plus albumin.18
Acute variceal bleeding was initially managed with either
somatostatin or terlipressin associated with emergency scler-
otherapy or band ligation. Prevention of recurrent bleeding was
performed with the administration of b-blockers with or
without variceal band ligation.19 20 Acute hepatic encephalo-
pathy was treated with lactulose and rectal enemas, and
treatment of the precipitating cause, if any.17
During the study period (January 2000 to March 2005), the
allocation of livers for transplantation in our centre was strictly
determined by the time on the waiting list; in other words,
when a liver from a cadaveric donor became available, the liver
was assigned to the patient who had been on the waiting list for
the longest time, matched by ABO group and body weight.
Living-related liver transplantation was offered to suitable
candidates. Since April 2005, the allocation of livers in our
transplant programme is based on the severity of liver disease
using the MELD score.
End-points and definit ions
The primary end-points of the study were survival before
transplantation at 3 and 12 months after inclusion on the
waiting list. The MELD score at inclusion was calculated
according to the formula of the United Network for Organ
Sharing (UNOS) available at www.unos.org. Hyponatraemia
was defined as serum sodium,130 mEq/l at the time of listing,
according to the definition of the International Ascites Club.21
Renal failure was defined as the presence of serum creatinine
>1.5 mg/dl at the time of listing. Hepatorenal syndrome was
diagnosed using the criteria of the International Ascites Club,
as reported elsewhere.22
Statistical analysis
Demographic, clinical and biochemical variables were analysed
as possible predictors of survival in a univariate analysis, and
probability curves (Kaplan–Meier) were compared with the log-
rank test. Values of biochemical variables included in the
statistical analysis were concurrent and obtained at the time of
inclusion of patients on the waiting list. Of all clinical and
biochemical variables analysed in the whole series of patients,
there were only a few missing values (bilirubin in 6 patients,
albumin in 6, international normalisation ratio (INR) in 5,
serum creatinine in 1, and MELD score in 9). Missing values
were considered as missing for the statistical analysis and were
not replaced by any values. Two different survival analyses were
performed: at 3 and 12 months after inclusion on the waiting
list. The 3-month survival analysis included all deaths occurring
between day 0 and day 90, while the 12-month survival
analysis included all deaths between day 0 and day 365.
Transplanted patients were considered as censored at the time
of transplantation. Twenty-four patients were censored for
transplantation at 3 months, and 174 patients were censored
for transplantation at 12 months. Patients removed from the
waiting list because of being ‘‘too sick’’ to be transplanted were
considered as dead at the time of exclusion from the waiting
list. Patients removed from the waiting list because of
improvement of their liver function and those removed because
of listing in another transplant centre were considered as
censored at the time of exclusion from the waiting list. Patients
still alive on the waiting list at the end of each period (3 and
12 months) were considered as censored. Predictive factors
identified in the univariate analysis were included in the
multivariable analysis, using Cox regression method. A step-
wise forward regression method was used. Validation of the
proportional hazards assumption for the final models (ie, that
the relative risk of failure between subgroups in the model does
not change over time) was carried out through a graphical
examination of log minus log plots of the Kaplan–Meier
survival curves versus the log of time, for the tertiles of the
model prediction.23 24 The final models were validated using the
bootstrap method.25 26
The accuracy of each independent predictive factor of survival
was assessed by receiver operating characteristic (ROC) curves.
Comparison between ROC curves (concordance c-statistic test)
was performed with the statistical package available at
www.analyse-it.com, which uses the algorithm described by
Hanley and McNeil.27 Statistical analysis was performed using
SPSS 10 for Windows (SPSS Inc., Chicago, IL, USA). Results are
expressed as mean (SD). p,0.05 was considered as statistically
significant. The study was approved by the Institutional Review
Board of the Hospital Clı´nic of Barcelona.
RESULTS
Characteristics of the patients
Demographic, clinical and biochemical data of patients
included in the study at the time of listing are shown in
table 1. One hundred and thirty-five (44%) of the 308 patients
had an abnormal serum sodium concentration (,135 mEq/l).
The prevalence of low serum sodium concentration as defined
by a serum sodium concentration ,130, ,125 and ,120 mEq/l
was 14, 5 and 1%, respectively.
Survival of patients on the waiting list
One-hundred and ninety (62%) out of the 308 patients included
in the study underwent liver transplantation during follow-up
(157 patients from deceased donors, 22 patients from living
donors and 11 patients received a domino liver transplanta-
tion), 65 patients (21%) died while in the waiting list, 18
patients (6%) were removed because of listing in another
transplant centre, 7 patients (2%) were excluded from the list
either because they were too sick to be transplanted (4 patients)
or because of marked improvement of liver function (3
patients), and 28 patients (9%) were still awaiting trans-
plantation at the time of the analysis of the results. The
median time on the waiting list was 6.4 months (range 0.1–
18 months). Figure 1 shows the probability of survival on the
waiting list of the whole population of included patients. The
probability of survival before transplantation was 88% at
3 months and 68% at 12 months after inclusion on the waiting
list.
Predictive factors of survival on the waiting list
The predictive factors of survival were analysed at two different
time points: 3 and 12 months.
Three-month survival
Thirty-four (11%) of the 308 patients died within the first
3 months after inclusion on the waiting list before transplanta-
tion was performed. Table 2 shows the comparison of clinical
and biochemical characteristics of patients who died and those
of patients who survived the initial 3 months. Factors
associated with 3-month survival in the univariate analysis
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were: hepatorenal syndrome, uncontrolled ascites, serum
bilirubin, serum albumin, INR, serum sodium concentration
and MELD score. All these variables were included in the
multivariable analysis as they were considered clinically
relevant. In multivariable analysis, only serum sodium and
MELD score were independently associated with prognosis
(table 3). When the MELD score was excluded from the
multivariable analysis, factors that were independently asso-
ciated with prognosis were: serum bilirubin, serum creatinine
and serum sodium concentration. Figure 2 shows the individual
relationship between serum sodium and MELD score and 3-
month probability of survival. There was a 12% increase in the
risk of death for each unit (mEq/l) decrease in serum sodium
concentration between 120 and 135 mEq/l. Similarly, for each
unit of increase in MELD score (between 15 and 40), the risk of
death increased by 8%. The area under the ROC curves for
MELD score and serum sodium were 0.79 (95% CI 0.71–0.86)
and 0.83 (95% CI 0.76–0.90), respectively, the difference not
being statistically significant (p = 0.4).
Twelve-month survival
Sixty-four (21%) of the 308 patients died within the first
12 months after inclusion on the waiting list before transplan-
tation was performed. Table 4 shows the comparison of clinical
and biochemical characteristics of patients who died and those
of patients who survived within the initial 12-month period.
Factors associated with 12-month survival in the univariate
analysis were: hepatic encephalopathy, hepatorenal syndrome,
uncontrolled ascites, renal failure, serum bilirubin, INR, serum
albumin, serum sodium concentration and MELD score. All
these variables were included in the multivariable analysis as
they were considered clinically relevant. In multivariable
analysis, again serum sodium and MELD score were indepen-
dently associated with prognosis (table 3). MELD score at
listing in patients transplanted during the 12-month period
(n = 190) was 15.9 (4.2) compared with 21 (5) in patients who
died during the same period (n = 64). Corresponding values of
serum sodium at listing were 136 (4) vs 132 (6) mEq/l,
respectively (p,0.05 for both). When the MELD score was
excluded from the multivariable analysis, factors that were
independently associated with prognosis were: serum bilirubin,
serum creatinine, INR and serum sodium concentration.
Figure 3 shows the probability of survival during the first year
after inclusion on the waiting list for all patients classified
according to different values of serum sodium and MELD score.
The area under the ROC curves for MELD score and serum
sodium were 0.77 (95% CI 0.70 to 0.80) and 0.70 (95% CI 0.60
to 0.78), respectively, the difference not being statistically
significant (p = 0.14).
To assess the possible value of serum sodium in improving
the accuracy of the MELD score in the evaluation of prognosis,
serum sodium concentration was incorporated in the calcula-
tion of the MELD score, using a formula described recently.28 A
MELD-Na score was then calculated for each patient and its
accuracy in predicting prognosis was compared with that of the
MELD score and serum sodium using ROC curves. As shown in
fig 4, no significant differences were observed between the
predictive value of MELD-Na at 3 and 12 months and those of
the MELD score and serum sodium concentration calculated
individually. The addition of the variable uncontrolled ascites to
MELD-Na did not significantly improve the accuracy of MELD
alone or MELD-Na in the prediction of 3- or 12-month sur-
vival (area under the ROC curve for 3-month survival: MELD
0.79, MELD-Na 0.83, MELD-Na-uncontrolled ascites 0.84;
area under the ROC curve for 12-month survival: MELD
0.76; MELD-Na 0.78, MELD-Na-uncontrolled ascites 0.77).
Moreover, when a separate analysis was performed in the
subgroup of patients with low MELD (,21),8 no significant
differences were found between the predictive values of
MELD-Na and MELD-Na-uncontrolled ascites and those of
MELD score or serum sodium individually (area under the ROC
curve for 3-month survival: MELD 0.74, serum sodium 0.79,
MELD-Na 0.80, MELD-Na-uncontrolled ascites 0.81; area under
the ROC curve for 12-month survival: MELD 0.70, serum
sodium 0.62, MELD-Na 0.70, MELD-Na-uncontrolled ascites
0.60).
Table 1 Demographic and clinical data and liver and
renal function tests at the time of listing for transplantation in
the 308 patients included in the study
Age (years) 52 (9) (18–66)
Sex
Male 207 (67%)
Female 101 (33%)
Aetiology of cirrhosis
Hepatitis C 136 (44%)
Alcohol 80 (26%)
Hepatitis C and alcohol 25 (8%)
Hepatitis B 20 (6%)
Other* 47 (18%)
Complications of cirrhosis
Ascites 271 (88%)
Controlled 112 (41%)
Uncontrolled 159 (59%)
Hepatic encephalopathy 145 (47%)
Variceal bleeding 91 (29%)
SBP 83 (27%)
Renal failure 39 (13%)
Hepatorenal syndrome` 20 (7%)
Parenchymal renal disease 19 (6%)
Bilirubin (mg/dl)1 4.3 (5) (0.2–46)
Albumin (g/l) 30 (5) (17–45)
Prothrombin time
Ratio 54 (16) (14–100)
INR 1.5 (0.8) (1–12)
Creatinine (mg/dl) 1.2 (0.9) (0.3–11)
Sodium (mEq/l) 135 (5) (111–146)
MELD score 18 (5) (7–48)
Child–Pugh score 9.3 (1.8) (5–15)
INR, international normalisation ratio; MELD, model for end-stage liver
disease; SBP, spontaneous bacterial peritonitis.
Data are expressed as as number (%) or mean (SD) (ranges)
*Other causes of end-stage liver disease were: cholestatic liver disease in 25
patients (8%), metabolic liver disease in 12 patients (4%), cryptogenic
cirrhosis in 5 patients (2%), autoimmune liver disease in 3 patients (1%) and
Budd–Chiari in 2 patients (1%).
As defined by serum creatinine >1.5 mg/dl.
`All 20 patients had type 2 hepatorenal syndrome.
1To convert mg/dl into mmol/l multiply by 17.1.
To convert mg/dl into mmol/l multiply by 16.6.
Figure 1 One-year survival before transplantation of the whole
population of patients with cirrhosis included in the study. Time 0 is the time
of listing. Numbers under the graph are patients at risk at each time point.
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Serum sodium and survival in different subpopulations
of patients with cirrhosis
To assess further the prognostic value of serum sodium
concentration, patients were categorised according to the major
complication(s) of cirrhosis they had developed before listing.
The prognostic value of serum sodium was then evaluated in
these subsets of patients by comparing the hazard ratio of death
at 3 months in patients with and without hyponatraemia. As
shown in table 5, the presence of hyponatraemia was associated
with an increased risk of death in all subpopulations of patients
evaluated: patients with ascites, hepatic encephalopathy,
gastrointestinal bleeding, spontaneous bacterial peritonitis or
renal failure. Serum sodium was an independent predictor of
survival in patients with low and high MELD scores (,21 and
>21, respectively).
DISCUSSION
The current study reports the results of the analysis of survival
and prognostic factors of a large cohort of patients with
cirrhosis listed for transplantation in a single institution over a
5-year period. Several characteristics of this cohort make it
unique in the assessment of prognostic factors of survival of
patients with cirrhosis awaiting liver transplantation. First, it
includes a relatively large number of patients treated in a single
institution following standardised protocols for the manage-
ment of complications of cirrhosis developing during the
waiting time. Secondly, the study period was restricted to 5
years, which minimises the impact of changes in patients’
management over time. Thirdly, during the period of the study,
the major determinant of organ allocation was time on the
waiting list. Finally, although this is a retrospective study, all
variables evaluated as prognostic factors were collected
prospectively in a large database at the time of inclusion of
patients on the waiting list.
The results of the current study confirm previous data
indicating that the MELD score is an independent predictor of
survival in patients with cirrhosis awaiting liver transplanta-
tion.29 30 MELD score at the time of listing was an independent
predictor of survival at both 3 and 12 months after inclusion of
patients on the waiting list. The fact that the allocation of
organs in this cohort of patients was done by time on the
waiting list reinforces the value of the MELD score as the best
method currently available to allocate organs when a system
based on the severity of the liver disease is to be used.
Comparison of ROC curves assessing the relationship between
MELD score and 3- and 12-month survival probability indicates
that the MELD score has a similar prognostic accuracy in the
assessment of 3-month survival compared with 12-month
survival (c-statistic 0.79 and 0.77, respectively). Moreover, a
close look at the relationship between MELD score and 3-
month survival probability indicates that a major change in
survival probability occurs in values of MELD ranging from 15
to 40 (fig 2). In this range, an increase in one point in the
MELD score represents an 8% decrease in 3-month survival
probability. Another interesting finding of the current study
was that patients with a MELD score lower than 15 have a very
high probability of survival at both 3 and 12 months after
listing (96 and 87%, respectively). This survival probability is
similar to that reported in most transplant centres after
transplantation of patients with cirrhosis.31 32 Patients with
low MELD scores are commonly listed for transplantation in
transplant programmes using allocation systems based on time
on the waiting list, as was the case in the current study.
However, the current data showing very low waiting list
mortality in this patient population cast doubts about the
convenience of listing patients with low MELD scores in
transplant programmes in which the allocation system is based
on the severity of liver disease. An interesting and somewhat
surprising finding of the current study was that hepatorenal
syndrome, although significantly associated with prognosis in
Table 2 Comparison of clinical and biochemical characteristics of patients who died and
those of patients who survived the initial 3-month period
Dead (n = 34) Alive (n = 274) p Value Likelihood ratio
Age (years) 53 (8) 52 (9) 0.37
Ascites 33 (97%) 238 (87%)
Controlled 6 (18%) 106 (44%) 0.004 7.25
Uncontrolled 27 (82%) 132 (56%)
Hepatic encephalopathy 18 (53%) 127 (46%) 0.58 0.49
GI bleeding 10 (29%) 81 (29%) 0.57 0.001
SBP 12 (35%) 71 (26%) 0.37
Renal failure* 6 (17%) 33 (12%) 0.48 0.77
Hepatorenal syndrome 6 (17%) 14 (5%) 0.026 5.21
Bilirubin (mg/dl) 8.5 (8.4) 3.6 (3.1) 0.000
Albumin (g/l) 28 (5) 31 (5) 0.000
INR 1.8 (0.5) 1.6 (0.9) 0.025
Creatinine (mg/dl) 1 (0.3) 1.2 (1.1) 0.416
Sodium (mEq/l) 130 (6) 136 (4) 0.000
MELD score 21 (5) 16 (5) 0.000
GI, gastrointestinal; INR, international normalisation ratio; MELD, model for end-stage liver disease.
*As defined by serum creatinine >1.5 mg/dl.
All patients had type 2 hepatorenal syndrome.
Table 3 Regression coefficients, odds ratios and 95% CI of
odds ratios of variables with independent predictive value of
survival at 3 and 12 months*
Coefficient OR (95% CI)
3 months
MELD 0.102 1.1 (1.07 to 1.142)
Serum sodium 20.095 0.90 (0.87 to 0.94)
12 months
MELD 0.088 1.091 (1.05 to 1.138)
Serum sodium 20.128 0.88 (0.845 to 0.916)
MELD, model for end-stage liver disease; OR, odds ratio.
*Both models were validated with the bootstrap method. In the bootstrap
validations for both models, the same variables entered the bootstrap-
derived models most frequently. In fact, MELD score and serum sodium
concentration appeared in 94 and 100% of the analyses for 3-month
survival, and in 100 and 99% of the analyses for 12-month survival,
respectively. Moreover, estimated models using only MELD score and serum
sodium concentration as independent predictors were observed in 76% at
3 months. At 12 months, the mentioned model was estimated in 38% of the
bootstrapped samples, and in only 1% of the models these two predictors did
not appear simultaneously.
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the univariate analysis, was not an independent predictive
factor of survival in the multivariable analysis. Although we do
not have a complete explanation for this finding, it may be due,
at least in part, to the fact that most patients with hepatorenal
syndrome were treated with terlipressin and albumin before
transplantation,18 which could have resulted in an improve-
ment of survival of these patients.
The results of the current study are in keeping with several
recent studies in patients with cirrhosis awaiting liver
transplantation as well as with previous studies in patients
with cirrhosis and ascites indicating that serum sodium
concentration is a very good marker of survival, at both 3 and
12 months after inclusion of patients on the waiting list.8–10
Serum sodium concentration has also recently been shown to
be a good marker of outcome after transplantation.33
Comparison of ROC curves assessing the relationship between
serum sodium concentration and 3- and 12-month survival
probability indicates that serum sodium concentration has
better prognostic accuracy in the assessment of 3-month
survival than 12-month survival (c-statistic 0.83 and 0.70,
respectively). On the other hand, a close look at the relationship
between serum sodium concentration and 3-month survival
probability indicates that a major change in survival probability
occurs in values of serum sodium ranging from 120 to 135
(fig 2). In this range, a reduction in 1 mEq/l in serum sodium
concentration is associated with a 12% decrease in 3-month
survival probability. Another relevant clinical finding of this
study was that patients without hyponatraemia but with a
serum sodium concentration lower than normal values (ie,
patients with serum sodium between 130 and 135 mEq/l) have
a 12-month probability of survival significantly greater than
that of patients with hyponatraemia (serum sodium
.130 mEq/l) but lower than that of patients with normal
serum sodium concentration (fig 3).
The reason why the MELD score is a good marker of
prognosis in patients with cirrhosis who are candidates for liver
transplantation is probably related to the fact that MELD
combines two parameters, bilirubin and INR, that are sensitive
markers of liver function, together with serum creatinine, a
marker of renal function.2 The severity of both liver and renal
dysfunction has been shown to correlate with prognosis in
patients with cirrhosis.34 35 In contrast, the explanation for why
serum sodium concentration is a good marker of prognosis in
patients with cirrhosis is uncertain and has not been
specifically investigated. It might be that serum sodium
concentration reflects the severity of liver failure, because
patients with hyponatraemia commonly have a more advanced
liver disease compared with that of patients without hypona-
traemia.33 36 However, the results of this study as well as those
from several previous studies8–10 indicate that the prognostic
value of hyponatraemia is independent of that of the MELD
score, which appears to dissociate the predictive value of serum
sodium from that of liver and renal failure. Alternatively, it is
possible that serum sodium concentration predicts prognosis
Figure 2 Relationship between serum
sodium (left) and model for end-stage liver
disease (MELD) score (right) and estimated
3-month probability of survival in all patients
included.
Table 4 Comparison of clinical and biochemical characteristics of patients included in the
study divided according to whether they were dead or alive at 12 months
Dead (n = 64) Alive (n = 244) p Value Likelihood ratio
Age (years) 52 (10) 52 (9) 0.9
Ascites 60 (94%) 211 (87%)
Controlled 14 (23%) 98 (46%) 0.001 9.3
Uncontrolled 46 (77%) 113 (54%)
Hepatic encephalopathy 38 (59%) 107 (44%) 0.02 4.7
GI bleeding 20 (21%) 71 (29%) 0.42 0.1
SBP 19 (30%) 64 (26%) 0.348 0.28
Renal failure* 13 (20%) 26 (11%) 0.04 3.8
Hepatorenal syndrome 9 (15%) 11 (5%) 0.01 6.38
Bilirubin (mg/dl) 6.7 (7.1) 3.7 (3.5) 0.002
Albumin (g/l) 28 (5) 31 (5) 0.000
INR 2 (1) 1.6 (0.8) 0.03
Creatinine (mg/dl) 1.2 (1.1) 1.2 (1.0) 0.453
Sodium (mEq/l) 132 (6) 136 (4) 0.000
MELD score 21 (6) 16 (5) 0.000
GI, gastrointestinal; INR, international normalisation ratio; MELD, model for end-stage liver disease; SBP, spontaneous
bacterial peritonitis.
*As defined by serum creatinine >1.5 mg/dl.
All patients had type 2 hepatorenal syndrome.
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because it reflects the severity of circulatory failure associated
with advanced cirrhosis, as hyponatraemia is due to a non-
osmotic hypersecretion of vasopressin, which in turn is
dependent on the degree of impairment in circulatory
function.21 22 37 Finally, hyponatraemia has been reported as a
predisposing factor for the development of hepatic encephalo-
pathy,38–40 although evidence supporting such a relationship is
still limited.
Considering the results of previous studies as well as those of
the current study, the question arises as to whether serum
sodium concentration should be used to improve the prognostic
accuracy of the MELD score in view of its simplicity and high
predictive value. To assess the possible value of serum sodium
in improving the accuracy of the MELD score in the evaluation
of prognosis, serum sodium concentration was incorporated in
the calculation of the MELD score, using a formula described
recently.28 A MELD-Na score was then calculated for each
patient and its accuracy in predicting prognosis was compared
with that of the MELD score and serum sodium using ROC
curves. As shown in fig 4, no significant differences were
observed between the predictive value of MELD-Na at 3 and
12 months and those of MELD score and serum sodium
concentration calculated individually. Discrepancies between
the results of the current study and those of previous studies10 28
may be related to differences in the patient population,
methods used to incorporate sodium in the MELD formula or
the method used for organ allocation. On the other hand, it is
important to point out that the sample size of the current study
was not high enough to rule out completely a better predictive
value of MELD-Na compared with MELD or serum sodium
alone. In fact, the estimated power of the study was low, 11% at
3 months and 30% at 12 months. An estimated power .80%
would have required the inclusion of 1268 patients which is
difficult to achieve in single-centre studies, unless the study
period is markedly prolonged, an approach that does not seem
appropriate because it will increase the heterogeneity of the
patient population. Therefore, multicentre studies with very
large sample sizes would be required to test the superiority of
MELD-Na with respect to MELD alone in the assessment of
prognosis of patients with cirrhosis awaiting liver transplanta-
tion.
While awaiting the results of these studies, it is important to
ponder the appropriateness of including serum sodium as a new
variable in a score for organ allocation in liver transplantation. A
Figure 3 One year-survival before
transplantation of the whole population of
patients with cirrhosis according to different
values of serum sodium (left) and model for
end-stage liver disease (MELD) score (right).
Figure 4 Receiver operating characteristic
(ROC) curves of the model for end-stage liver
disease (MELD) score (c-statistic (SEM) 0.79
(0.04) at 3 months and 0.77 (0.03) at
12 months), serum sodium concentration (c-
statistic (SEM) 0.82 (0.03) and 0.70 (0.04),
at 3 and 12 months, respectively) and MELD
plus serum sodium concentration (c-statistic
(SEM) 0.83 (0.03) and 0.77 (0.03), at 3 and
12 months, respectively), and survival
probability at 3 (left) and 12 months (right).
MELD plus serum sodium concentration was
calculated as described in Hosmer and
Lemeshow.23 p = not significant for all
comparisons.
1288 London˜o, Ca´ rdenas, Guevara, et al
www.gutjnl.com
 group.bmj.com on April 1, 2011 - Published by gut.bmj.comDownloaded from 
new variable should ideally meet the following criteria: good
correlation with survival; easy measurement; wide availability;
and stability. While serum sodium meets the first three criteria, it
does not meet the fourth. In fact, serum sodium levels may have
important fluctuations after simple therapeutic manoeuvres,
which do not necessarily reflect changes in the severity of the
disease. For example, administration of diuretics is commonly
associated with marked changes in serum sodium concentration,
which are of 4 mEq/l on average and can be as high as 10–
15 mEq/l, and are often reversible after diuretic withdrawal.42
Moreover, serum sodium may decrease markedly after adminis-
tration of oral or intravenous hypotonic fluids due to the impaired
capacity to eliminate solute-free water commonly present in
patients with advanced cirrhosis.43 Finally, the serum sodium
concentration increases markedly after the administration of
drugs that antagonise selectively the V2 receptors of the
antidiuretic hormone. Phase 2 studies have shown that these
drugs increase serum sodium concentration and improve the
management of ascites in patients with cirrhosis and hypona-
traemia, and may be available soon for use in clinical practice.44–46
If the beneficial effects of these drugs are confirmed in phase 3
studies, which are currently underway, the addition of serum
sodium as a variable in a new score to be used for organ allocation
may be an obstacle for the use of these drugs in patients awaiting
liver transplantation.
In conclusion, the results of the current study indicate that
the MELD score and serum sodium concentration are the only
independent predictive factors of 3- and 12-month survival in
patients with cirrhosis awaiting liver transplantation. Serum
sodium concentration is equally accurate in the assessment of
prognosis in different subpopulations of patients with cirrhosis
categorised according to the major complication developed
before listing in our patient population. The addition of serum
sodium to the MELD score does not appear to improve
significantly the prognostic accuracy of the MELD score alone.
Nevertheless, additional studies in large patient populations
should be performed to address this issue further.
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